FDA Should Consider Raising Evidence Standards For Approval, Blues Say
FDA should consider bringing evidence requirements for drug applications in line with Medicare's coverage decision standard, Blue Cross Blue Shield Association suggested in comments to HHS
You may also be interested in...
Providing higher reimbursement for first-in-class drugs is one way to boost innovation in the U.S., FasterCures says in comments to HHS
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials